The insights gained from this coeliac disease organoid model provide a valuable platform for exploring novel therapeutic interventions targeting the IL-7 pathway. Since IL-7 has been identified as a gluten-inducible pathogenic modulator that plays a crucial role in regulating CD8+ T-cell NKG2C/D expression and promoting epithelial destruction in CeD, targeting this pathway could offer promising treatment strategies. By understanding the specific mechanisms through which IL-7 influences immune responses and epithelial damage in CeD organoids, researchers can develop targeted therapies that aim to modulate IL-7 signaling. This could involve the development of IL-7 inhibitors or antagonists to disrupt the IL-7 pathway and prevent the destructive immune responses triggered by gluten peptides in CeD patients. Additionally, the organoid model can be used to screen and test potential therapeutic compounds that target IL-7 or its downstream effectors, providing a more efficient and accurate way to identify effective treatments for CeD.